Get the Stockscreener App
1.63
16.84%
-0.33
Pre-market:
1.69
0.06
+3.68%
Pyxis Oncology Inc stock is traded at $1.63, with a volume of 1.28M.
It is down -16.84% in the last 24 hours and down -14.21% over the past month.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
See More
Previous Close:
$1.96
Open:
$2
24h Volume:
1.28M
Relative Volume:
2.81
Market Cap:
$103.27M
Revenue:
$13.86M
Net Income/Loss:
$-79.62M
P/E Ratio:
-1.27
EPS:
-1.2835
Net Cash Flow:
$-63.51M
1W Performance:
-14.66%
1M Performance:
-14.21%
6M Performance:
-69.13%
1Y Performance:
+32.52%
1-Day Range:
$1.5717
$2.0431
1-Week Range:
$1.5717
$2.09
52-Week Range:
$0.97
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Name
Pyxis Oncology Inc
Sector
Industry
Phone
(617) 221-9059
Address
321 HARRISON AVENUE, BOSTON
Compare PYXS vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
1.63 | 124.18M | 13.86M | -79.62M | -63.51M | -1.2835 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Nov-21-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-08-24 | Initiated | Stephens | Overweight |
| Aug-08-24 | Initiated | Stifel | Buy |
| May-07-24 | Resumed | Jefferies | Buy |
| Feb-09-24 | Initiated | BTIG Research | Buy |
| Jan-23-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-02-21 | Initiated | BofA Securities | Neutral |
| Nov-02-21 | Initiated | Credit Suisse | Outperform |
| Nov-02-21 | Initiated | Jefferies | Buy |
View All
Pyxis Oncology Inc Stock (PYXS) Latest News
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $6 - Moomoo
PYXS: MICVO demonstrates high efficacy and improved safety in head and neck cancer with dose capping - TradingView
Pyxis Oncology (PYXS) Rating Reiterated as Buy by HC Wainwright & Co. | PYXS Stock News - GuruFocus
LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Raises Target Price to $6 - Moomoo
RBC Capital Keeps Their Buy Rating on Pyxis Oncology (PYXS) - The Globe and Mail
Pyxis Oncology (PYXS) Gets a Buy from Guggenheim - The Globe and Mail
Wedbush Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $6 - Moomoo
A Quick Look at Today's Ratings for Pyxis Oncology(PYXS.US), With a Forecast Between $5 to $7 - Moomoo
Pyxis Oncology (PYXS) Cash Runway Under One Year Reinforces Bearish Funding Narratives - Sahm
Pyxis Oncology Faces Urgent Capital Needs and Potential Dilution Risks Amid Market Volatility - TipRanks
Pyxis Oncology, Inc. Faces Substantial Doubt as a Going Concern and Requires Additional Capital – 2026 Q1 Financial Report Highlights Risks and Challenges 25 - Minichart
Pyxis Oncology Shares Slide on Steeper 1Q Loss - Moomoo
Pyxis Oncology Reports Q1 2026 Financial Results and Advances MICVO ADC Toward Key Clinical Milestones in Head and Neck Cancer - Minichart
Pyxis Oncology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Pyxis Oncology stock (US70611B1026): Q1 2026 loss widens to $23.3M - AD HOC NEWS
Pyxis Oncology (PYXS) Q1 2026 loss deepens as MICVO trials expand and cash runway tightens - Stock Titan
Pyxis Oncology (PYXS) posts $23.3M Q1 loss and advances MICVO trials - Stock Titan
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones - marketscreener.com
BRIEF-Pyxis Oncology Q1 Net Income USD -23.272 Million - TradingView
Pyxis Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Should You Sell Pyxis Oncology (PYXS) After -18.89% Drop? 2026-05-14Viral Trades - newser.com
Pyxis Oncology to Participate in Upcoming Investor Conferences - Caledonian Record
Cancer drug developer Pyxis Oncology plans investor webcasts - Stock Titan
Pyxis Oncology (PYXS) Upgraded to Strong Buy: Here's What You Should Know - MSN
Pyxis Oncology stock (US70611B1026): Builds $540M cash pile after Q1 loss - AD HOC NEWS
Pyxis Oncology Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
TradingKey - TradingKey
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer - The Manila Times
SEC EDGAR Submission 0000950170-23-023950 - SEC.gov
Pyxis brings in former ImmunoGen dealmaker to advance MICVO - Stock Titan
Pyxis Oncology, Inc. Appoints Nelson Azoulay as Chief Business Officer - marketscreener.com
Wedbush Initiates Pyxis Oncology at Outperform With $6 Price Target - marketscreener.com
Wedbush initiated coverage on Pyxis Oncology with a new price target - Quantisnow
Wedbush Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $6 - Moomoo
Pyxis Oncology (PYXS) Price Target Increased by 13.33% to 6.94 - MSN
Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 14.7% - MarketBeat
Pyxis Oncology, Inc. Files Amended 8-K/A Report for 2026 with SEC – Company Details, Address, and Nasdaq Listing - Minichart
Pyxis Oncology (PYXS) Management Strategy | Pyxis Oncology posts 15.6% EPS beat, no revenueDebt Analysis - newser.com
[ARS] Pyxis Oncology, Inc. SEC Filing - Stock Titan
Pyxis Oncology | DEFA14A: Others - Moomoo
Pyxis Oncology (NASDAQ: PYXS) details 2026 vote on directors and auditor - Stock Titan
Pyxis Oncology | 8-K/A: Current report (Amendment) - Moomoo
Lara Sullivan exit package at Pyxis Oncology (NASDAQ: PYXS) - Stock Titan
PYXS Pyxis Oncology beats Q4 2025 loss estimates, but shares shed 2.35 percent amid weak investor reaction.EBIT Margin - Newser
PYXS Pyxis Oncology Q4 2025 narrower than expected per share loss sparks double digit share price jump today.Community Driven Stock Picks - newser.com
PYXS Stock: Analyzing Pyxis Oncology's Market Performance - Bitget
Pyxis Oncology (PYXS) Cantor Global Healthcare Conference 2025 Summary - Quartr
Pyxis Oncology (PYXS) Morgan Stanley 22nd Annual Global Healthcare Conference summary - Quartr
Pyxis Oncology (PYXS) Registration Filing Summary - Quartr
Pyxis Oncology (PYXS) H.C. Wainwright 26th Annual Global Investment Conference summary - Quartr
Pyxis Oncology (PYXS) Proxy Filing Summary - Quartr
Pyxis Oncology Inc Stock (PYXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):